Advertisement
U.S. markets open in 7 hours 38 minutes
Advertisement

Laekna, Inc. (2105.HK)

HKSE - HKSE Delayed Price. Currency in HKD
14.920-1.940 (-11.51%)
As of 02:36PM HKT. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close16.860
Open16.620
Bid14.980 x N/A
Ask15.180 x N/A
Day's Range14.600 - 16.660
52 Week Range10.320 - 26.450
Volume395,500
Avg. Volume690,765
Market Cap5.82B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.950
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 2105.HK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Laekna, Inc. (2105.HK) Announces Interim Results 2023

      Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, announced today the interim results for the six months ended June 30, 2023, and provided the latest updates on the clinical and preclinical development of its drug candidates.